CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.974
EU - Europa 9.994
AS - Asia 8.198
SA - Sud America 1.038
AF - Africa 177
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 14
Totale 30.410
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.799
RU - Federazione Russa 3.701
SG - Singapore 3.171
CN - Cina 2.754
GB - Regno Unito 2.143
IT - Italia 908
BR - Brasile 793
VN - Vietnam 668
HK - Hong Kong 646
DE - Germania 620
FR - Francia 608
FI - Finlandia 540
IE - Irlanda 497
SE - Svezia 490
KR - Corea 269
IN - India 140
BD - Bangladesh 135
NL - Olanda 113
UA - Ucraina 104
AR - Argentina 87
CA - Canada 82
JP - Giappone 63
ID - Indonesia 55
TR - Turchia 53
PL - Polonia 49
MX - Messico 48
ZA - Sudafrica 48
EC - Ecuador 47
IQ - Iraq 45
ES - Italia 40
BE - Belgio 33
CH - Svizzera 28
AT - Austria 25
CO - Colombia 25
PK - Pakistan 25
MA - Marocco 24
VE - Venezuela 23
CL - Cile 22
NG - Nigeria 22
SA - Arabia Saudita 18
PY - Paraguay 17
UZ - Uzbekistan 16
IR - Iran 15
PH - Filippine 15
EU - Europa 14
NP - Nepal 14
CZ - Repubblica Ceca 13
LT - Lituania 13
TN - Tunisia 13
EG - Egitto 12
KE - Kenya 12
MY - Malesia 12
PE - Perù 12
AZ - Azerbaigian 11
TG - Togo 11
AU - Australia 10
AE - Emirati Arabi Uniti 9
TH - Thailandia 9
AL - Albania 8
BJ - Benin 8
CR - Costa Rica 8
LV - Lettonia 8
DZ - Algeria 7
HN - Honduras 7
OM - Oman 7
PT - Portogallo 7
BO - Bolivia 6
GR - Grecia 6
JM - Giamaica 6
NI - Nicaragua 6
RS - Serbia 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
IL - Israele 5
JO - Giordania 5
AM - Armenia 4
KZ - Kazakistan 4
MK - Macedonia 4
NO - Norvegia 4
UY - Uruguay 4
BG - Bulgaria 3
CI - Costa d'Avorio 3
CM - Camerun 3
CY - Cipro 3
GA - Gabon 3
GE - Georgia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
RO - Romania 3
SI - Slovenia 3
SN - Senegal 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
EE - Estonia 2
KH - Cambogia 2
LU - Lussemburgo 2
Totale 30.373
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Singapore 1.587
San Jose 1.186
Moscow 1.145
Chandler 1.084
Ashburn 973
Woodbridge 955
Dallas 846
Hong Kong 638
Ann Arbor 620
Dublin 492
Beijing 472
Jacksonville 444
The Dalles 435
Houston 412
Verona 363
Jinan 247
Council Bluffs 244
Ho Chi Minh City 238
Lawrence 236
Princeton 236
New York 213
Wilmington 192
Nanjing 187
Los Angeles 186
Munich 186
Shenyang 157
Hanoi 155
Helsinki 131
Hebei 118
Buffalo 106
Redondo Beach 106
Tianjin 106
Changsha 80
Santa Clara 80
Ningbo 77
São Paulo 74
Milan 71
Haikou 70
Guangzhou 62
Zhengzhou 60
Nanchang 59
Hangzhou 57
Sindelfingen 54
Tokyo 54
Columbus 53
Jiaxing 49
London 49
Taizhou 47
Seoul 45
Frankfurt am Main 43
Orem 39
Turku 39
Taiyuan 38
Seattle 37
Chennai 36
Brussels 33
Fuzhou 30
Warsaw 30
Chicago 29
Montreal 29
Rio de Janeiro 29
Rome 28
San Francisco 28
Brooklyn 27
Amsterdam 26
Boardman 26
Johannesburg 26
Lanzhou 26
Norwalk 26
Denver 25
Falls Church 24
Redwood City 24
Dearborn 23
Lancaster 22
Mexico City 22
Abuja 21
Mumbai 21
Stockholm 21
Da Nang 20
Haiphong 20
Phoenix 20
Quito 20
Atlanta 19
Baghdad 19
Jakarta 18
Zurich 18
Hải Dương 17
Nuremberg 17
Belo Horizonte 16
Bologna 16
Boston 16
Porto Alegre 16
Meda 15
Biên Hòa 14
Charlotte 14
Curitiba 14
Madrid 14
Poplar 14
Shanghai 14
Totale 18.802
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 312
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 287
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 249
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 245
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 241
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 235
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 226
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 219
Adenocarcinoma of the paraurethral glands: a case report 213
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 213
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 212
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 212
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 207
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 201
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 201
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 201
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 199
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 199
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 198
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 198
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 196
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 194
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 192
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 192
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 191
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 190
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 189
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 187
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 186
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 184
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 183
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 180
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 180
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 178
The development of PARP as a successful target for cancer therapy 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 177
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 177
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 177
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 176
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 175
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 170
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 169
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 167
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 166
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 166
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 165
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies 165
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 164
Do immune checkpoint inhibitors need new studies methodology? 164
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 163
2-weekly docetaxel: issues for clinical practice. 160
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 160
Clinical meta-analyses of targeted therapies in adenocarcinoma. 158
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 157
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 156
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 156
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 155
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 152
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 150
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 149
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 146
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 145
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 145
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 145
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 144
Acute emesis: Moderately emetogenic chemotherapy. 143
Clinical meta-analyses of targeted therapies in adenocarcinoma. 142
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 142
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 142
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 139
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 137
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 137
Physical activity and exercise in lung cancer care: will promises be fulfilled? 136
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 135
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 134
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 134
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 133
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 132
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 132
Adjuvant chemotherapy for bladder cancer: the chance for meta-aalyses comparison 130
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 130
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 129
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 129
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 128
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 128
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 128
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 126
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 126
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 125
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 125
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 123
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 122
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 121
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 120
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 120
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. 120
Totale 16.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.865
article - articoli 102.693
book - libri 518
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.654
Totale 217.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/20221.660 104 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/20254.445 234 266 173 799 134 157 160 215 751 326 329 901
2025/202612.784 961 701 925 1.991 3.120 766 1.218 676 1.045 724 283 374
Totale 30.653